Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Opinion
Video
Real-World Clinical Experience With Ruxolitinib Cream Monotherapy to Manage Atopic Dermatitis
Author(s):
In this recently presented poster, a dermatology expert draws on clinical experience to reveal why healthcare providers switch treatments for atopic dermatitis (AD). The expert also examines how these reasons vary with disease stage and patient demographics, offering nuanced insights into AD management.
- In your experience, what are the most commonly cited reasons by healthcare providers for switching treatments in patients with AD?
- In your experience, how might these factors vary across different stages of the disease or patient populations?
- How do you interpret the implications of the majority of patients experiencing improved disease control upon transitioning to ruxolitinib cream, particularly concerning disease management strategies and patient outcomes?
Related Videos
Related Content
